Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAL2 antisense RNA 1 (MAL2-AS1) is a long noncoding antisense RNA gene annotated on the human genome. Like other antisense lncRNAs, it is transcribed from the strand opposite to its sense gene (in this case, MAL2), and is presumed to regulate gene expression through various mechanisms such as transcript interference, modulation of chromatin structure, or miRNA sponging[1][7]. Antisense RNAs may affect gene expression in *cis* (near their site of transcription) or in *trans* (at distant loci), often impacting the stability, translation, or transcription of their sense counterpart[1]. There are no reported diseases directly associated with MAL2-AS1, and it is not currently known as a therapeutic target or biomarker. Most information about its function and roles remains inferential, based on general mechanisms established for long noncoding antisense RNAs[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MAL2 antisense RNA 1 (MAL2-AS1).